DHEA improves symptomatic treatment of moderately and severely impaired MPTP monkeys

Neurobiology of Aging

Volumn 27, Issue 11, 2006, Pages 1684-1693

  Bélanger, Nancy ^a,b   Grégoire, Laurent ^a,b   Bédard, Paul J ^a,b   Di Paolo, Thérèse ^a,b  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

Author keywords

Dehydroepiandrosterone; Dyskinesia; l Dopa; MPTP monkeys; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; DOPAMINE; ESTRADIOL; LEVODOPA; PRASTERONE; STEROID;

AGING; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DEGENERATIVE DISEASE; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MEGADOSE; DYSKINESIA; FEMALE; GABAERGIC SYSTEM; HUMAN; LOW DRUG DOSE; MONKEY; MOTOR DYSFUNCTION; NONHUMAN; PALLIATIVE THERAPY; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; SCORING SYSTEM; TREATMENT OUTCOME;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; ANTIPARKINSON AGENTS; DEHYDROEPIANDROSTERONE; DYSKINESIA, DRUG-INDUCED; FEMALE; LEVODOPA; MACACA FASCICULARIS; MOTOR ACTIVITY; PARKINSONIAN DISORDERS; SEVERITY OF ILLNESS INDEX;

EID: 33748439626     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2005.09.028     Document Type: Article

References (75)

1. Albin R.L., Young A.B., and Penney J.B. The functional anatomy of basal ganglia disorders. Trends Neurosci 12 (1989) 366-375
2. Anderson G.L., Limacher M., Assaf A.R., Bassford T., Beresford S.A., Black H., et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 291 (2004) 1701-1712
3. Baulieu E.E. Neurosteroids, their role in brain physiology: neurotrophicity, memory, aging. Bull Acad Natl Med 185 (2001) 349-369 discussion 342-370
4. Baulieu E.E., and Robel P. Dehydroepiandrosterone and dehydroepiandrosterone sulfate as neuroactive neurosteroids. J Endocrinol 150 Suppl. (1996) S221-S239
5. Baulieu E.E., Thomas G., Legrain S., Lahlou N., Roger M., Debuire B., et al. Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: contribution of the DHEAge Study to a sociobiomedical issue. Proc Natl Acad Sci U S A 97 (2000) 4279-4284
6. Becker J.B. Gender differences in dopaminergic function in striatum and nucleus accumbens. Pharmacol Biochem Behav 64 (1999) 803-812
7. Bedard P., Langelier P., and Villeneuve A. Oestrogens and extrapyramidal system. Lancet 2 (1977) 1367-1368
8. Belanger A., Candas B., Dupont A., Cusan L., Diamond P., Gomez J.L., et al. Changes in serum concentrations of conjugated and unconjugated steroids in 40- to 80-year-old men. J Clin Endocrinol Metab 79 (1994) 1086-1090
9. Belanger N., Gregoire L., Bedard P., and Di Paolo T. Estradiol and dehydroepiandrosterone potentiate levodopa-induced locomotor activity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys. Endocrine 21 (2003) 97-101
10. Belanger N., Gregoire L., Hadj Tahar A., and Bedard P.J. Chronic treatment with small doses of cabergoline prevents dopa-induced dyskinesias in parkinsonian monkeys. Mov Disord 18 (2003) 1436-1441
11. Bergeron R., de Montigny C., and Debonnel G. Potentiation of neuronal NMDA response induced by dehydroepiandrosterone and its suppression by progesterone: effects mediated via sigma receptors. J Neurosci 16 (1996) 1193-1202
12. Berube R., Malenfant J., Gauvin D., Blais M., Gagnon E., Dumas R., et al. Quantification of androgenic and estrogenic steroids in rat and monkey serum using gas chromatography and negative chemical ionization mass spectrometry. Proceedings of the 48th ASMS Conference on Mass Spectrometry and Allied Topics. Long Beach, CA (2000)
13. Blanchet P.J., Fang J., Hyland K., Arnold L.A., Mouradian M.M., and Chase T.N. Short-term effects of high-dose 17beta-estradiol in postmenopausal PD patients: a crossover study. Neurology 53 (1999) 91-95
14. Brotchie J.M. Nondopaminergic mechanisms in levodopa-induced dyskinesia. Mov Disord 20 (2005) 919-931
15. Calon F., Hadj Tahar A., Blanchet P.J., Morissette M., Grondin R., Goulet M., et al. Dopamine-receptor stimulation: biobehavioral and biochemical consequences. Trends Neurosci 23 (2000) S92-S100
16. Calon F., Morissette M., Goulet M., Grondin R., Blanchet P.J., Bedard P.J., et al. Chronic D1 and D2 dopaminomimetic treatment of MPTP-denervated monkeys: effects on basal ganglia GABA(A)/benzodiazepine receptor complex and GABA content. Neurochem Int 35 (1999) 81-91
17. Calon F., Morissette M., Rajput A.H., Hornykiewicz O., Bedard P.J., and Di Paolo T. Changes of GABA receptors and dopamine turnover in the postmortem brains of parkinsonians with levodopa-induced motor complications. Mov Disord 18 (2003) 241-253
18. Calon F., Rajput A.H., Hornykiewicz O., Bedard P.J., and Di Paolo T. Levodopa-induced motor complications are associated with alterations of glutamate receptors in Parkinson's disease. Neurobiol Dis 14 (2003) 404-416
19. Cameron D.R., and Braunstein G.D. The use of dehydroepiandrosterone therapy in clinical practice. Treat Endocrinol 4 (2005) 95-114
20. Creutz L.M., and Kritzer M.F. Estrogen receptor-beta immunoreactivity in the midbrain of adult rats: regional, subregional, and cellular localization in the A10, A9, and A8 dopamine cell groups. J Comp Neurol 446 (2002) 288-300
21. Creutz L.M., and Kritzer M.F. Mesostriatal and mesolimbic projections of midbrain neurons immunoreactive for estrogen receptor beta or androgen receptors in rats. J Comp Neurol 476 (2004) 348-362
22. Cyr M., Calon F., Morissette M., and Di Paolo T. Estrogenic modulation of brain activity: implications for schizophrenia and Parkinson's disease. J Psychiatry Neurosci 27 (2002) 12-27
23. Cyr M., Calon F., Morissette M., Grandbois M., Di Paolo T., and Callier S. Drugs with estrogen-like potency and brain activity: potential therapeutic application for the CNS. Curr Pharm Des 6 (2000) 1287-1312
24. Czlonkowska A., Kurkowska-Jastrzebska I., Czlonkowski A., Peter D., and Stefano G.B. Immune processes in the pathogenesis of Parkinson's disease - a potential role for microglia and nitric oxide. Med Sci Monit 8 (2002) RA165-RA177
25. D'Astous M., Morissette M., Tanguay B., Callier S., and Di Paolo T. Dehydroepiandrosterone (DHEA) such as 17beta-estradiol prevents MPTP-induced dopamine depletion in mice. Synapse 47 (2003) 10-14
26. di Michele F., Caltagirone C., Bonaviri G., Romeo E., and Spalletta G. Plasma dehydroepiandrosterone levels are strongly increased in schizophrenia. J Psychiatr Res 39 (2005) 267-273
27. Di Paolo T. Modulation of brain dopamine transmission by sex steroids. Rev Neurosci 5 (1994) 27-41
28. Donahue J.E., Stopa E.G., Chorsky R.L., King J.C., Schipper H.M., Tobet S.A., et al. Cells containing immunoreactive estrogen receptor-alpha in the human basal forebrain. Brain Res 856 (2000) 142-151
29. Engel S.R., and Grant K.A. Neurosteroids and behavior. Int Rev Neurobiol 46 (2001) 321-348
30. Flynn M.A., Weaver-Osterholtz D., Sharpe-Timms K.L., Allen S., and Krause G. Dehydroepiandrosterone replacement in aging humans. J Clin Endocrinol Metab 84 (1999) 1527-1533
31. Genedani S., Rasio G., Cortelli P., Antonelli F., Guidolin D., Galantucci M., et al. Studies on homocysteine and dehydroepiandrosterone sulphate plasma levels in Alzheimer's disease patients and in Parkinson's disease patients. Neurotox Res 6 (2004) 327-332
32. Gerfen C.R., and Wilson C.J. In: Swanson L.W. (Ed). Handbook of chemical anatomy, integrated system in the CNS, Part III (1996), Elsevier, Amsterdam 371-468
33. Gomez-Mancilla B., and Bedard P.J. Effect of estrogen and progesterone on l-Dopa induced dyskinesia in MPTP-treated monkeys. Neurosci Lett 135 (1992) 129-132
34. Goyal R.O., Sagar R., Ammini A.C., Khurana M.L., and Alias A.G. Negative correlation between negative symptoms of schizophrenia and testosterone levels. Ann NY Acad Sci 1032 (2004) 291-294
35. Guennoun R., Fiddes R.J., Gouezou M., Lombes M., and Baulieu E.E. A key enzyme in the biosynthesis of neurosteroids, 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4-isomerase (3 beta-HSD), is expressed in rat brain. Brain Res Mol Brain Res 30 (1995) 287-300
36. Harris D.S., Wolkowitz O.M., and Reus V.I. Movement disorder, memory, psychiatric symptoms and serum DHEA levels in schizophrenic and schizoaffective patients. World J Biol Psychiatry 2 (2001) 99-102
37. Kalimi M., Shafagoj Y., Loria R., Padgett D., and Regelson W. Anti-glucocorticoid effects of dehydroepiandrosterone (DHEA). Mol Cell Biochem 131 (1994) 99-104
38. Kuppers E., and Beyer C. Expression of aromatase in the embryonic and postnatal mouse striatum. Brain Res Mol Brain Res 63 (1998) 184-188
39. Labrie C., Flamand M., Belanger A., and Labrie F. High bioavailability of dehydroepiandrosterone administered percutaneously in the rat. J Endocrinol 150 Suppl. (1996) S107-S118
40. Labrie F., Luu-The V., Labrie C., Belanger A., Simard J., Lin S.X., et al. Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone. Endocr Rev 24 (2003) 152-182
41. Laflamme N., Nappi R.E., Drolet G., Labrie C., and Rivest S. Expression and neuropeptidergic characterization of estrogen receptors (ERalpha and ERbeta) throughout the rat brain: anatomical evidence of distinct roles of each subtype. J Neurobiol 36 (1998) 357-378
42. Lang A.E., and Lozano A.M. Parkinson's disease. First of two parts. N Engl J Med 339 (1998) 1044-1053
43. Lang A.E., and Lozano A.M. Parkinson's disease. Second of two parts. N Engl J Med 339 (1998) 1130-1143
44. Leblanc M., Labrie C., Belanger A., Candas B., and Labrie F. Pharmacokinetics of oral dehydroepiandrosterone (DHEA) in the ovariectomised cynomolgus monkey. J Steroid Biochem Mol Biol 81 (2002) 159-164
45. Majewska M.D. Neuronal actions of dehydroepiandrosterone. Possible roles in brain development, aging, memory, and affect. Ann NY Acad Sci 774 (1995) 111-120
46. Majewska M.D., Demirgoren S., Spivak C.E., and London E.D. The neurosteroid dehydroepiandrosterone sulfate is an allosteric antagonist of the GABAA receptor. Brain Res 526 (1990) 143-146
47. Majewska M.D., and Vaupel D.B. Steroid control of uterine motility via gamma-aminobutyric acid A receptors in the rabbit: a novel mechanism?. J Endocrinol 131 (1991) 427-434
48. Marsden C.D. Function of the basal ganglia as revealed by cognitive and motor disorders in Parkinson's disease. Can J Neurol Sci 11 (1984) 129-135
49. Mehta A.K., and Ticku M.K. Unsulfated and sulfated neurosteroids differentially modulate the binding characteristics of various radioligands of GABA(A) receptors following chronic ethanol administration. Neuropharmacology 40 (2001) 668-675
50. Mermelstein P.G., Becker J.B., and Surmeier D.J. Estradiol reduces calcium currents in rat neostriatal neurons via a membrane receptor. J Neurosci 16 (1996) 595-604
51. Montgomery D.C. Design and analysis of experiments (1991), Wiley and Sons
52. Morales A.J., Nolan J.J., Nelson J.C., and Yen S.S. Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age. J Clin Endocrinol Metab 78 (1994) 1360-1367
53. Murray H.E., and Gillies G.E. Differential effects of neuroactive steroids on somatostatin and dopamine secretion from primary hypothalamic cell cultures. J Neuroendocrinol 9 (1997) 287-295
54. Osterlund M.K., Gustafsson J.A., Keller E., and Hurd Y.L. Estrogen receptor beta (ERbeta) messenger ribonucleic acid (mRNA) expression within the human forebrain: distinct distribution pattern to ERalpha mRNA. J Clin Endocrinol Metab 85 (2000) 3840-3846
55. Rajkowski K.M., Robel P., and Baulieu E.E. Hydroxysteroid sulfotransferase activity in the rat brain and liver as a function of age and sex. Steroids 62 (1997) 427-436
56. Rapp S.R., Espeland M.A., Shumaker S.A., Henderson V.W., Brunner R.L., Manson J.E., et al. Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 289 (2003) 2663-2672
57. Rossouw J.E., Anderson G.L., Prentice R.L., LaCroix A.Z., Kooperberg C., Stefanick M.L., et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288 (2002) 321-333
58. Shirayama Y., Hashimoto K., Suzuki Y., and Higuchi T. Correlation of plasma neurosteroid levels to the severity of negative symptoms in male patients with schizophrenia. Schizophr Res 58 (2002) 69-74
59. Shumaker S.A., Legault C., Rapp S.R., Thal L., Wallace R.B., Ockene J.K., et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 289 (2003) 2651-2662
60. Siderowf A., and Stern M. Update on Parkinson disease. Ann Intern Med 138 (2003) 651-658
61. Smith Y., Bevan M.D., Shink E., and Bolam J.P. Microcircuitry of the direct and indirect pathways of the basal ganglia. Neuroscience 86 (1998) 353-387
62. Strijks E., Kremer J.A., and Horstink M.W. Effects of female sex steroids on Parkinson's disease in postmenopausal women. Clin Neuropharmacol 22 (1999) 93-97
63. Strous R.D., and Dehydroepiandrosterone. (DHEA) augmentation in the management of schizophrenia symptomatology. Essent Psychopharmacol 6 (2005) 141-147
64. Strous R.D., Maayan R., Lapidus R., Goredetsky L., Zeldich E., Kotler M., et al. Increased circulatory dehydroepiandrosterone and dehydroepiandrosterone-sulphate in first-episode schizophrenia: relationship to gender, aggression and symptomatology. Schizophr Res 71 (2004) 427-434
65. Strous R.D., Maayan R., Lapidus R., Stryjer R., Lustig M., Kotler M., et al. Dehydroepiandrosterone augmentation in the management of negative, depressive, and anxiety symptoms in schizophrenia. Arch Gen Psychiatry 60 (2003) 133-141
66. Svec F., and Porter J.R. The actions of exogenous dehydroepiandrosterone in experimental animals and humans. Proc Soc Exp Biol Med 218 (1998) 174-191
67. Tomas-Camardiel M., Sanchez-Hidalgo M.C., Sanchez del Pino M.J., Navarro A., Machado A., and Cano J. Comparative study of the neuroprotective effect of dehydroepiandrosterone and 17beta-estradiol against 1-methyl-4-phenylpyridium toxicity on rat striatum. Neuroscience 109 (2002) 569-584
68. Vallee M., Mayo W., and Le Moal M. Role of pregnenolone, dehydroepiandrosterone and their sulfate esters on learning and memory in cognitive aging. Brain Res Brain Res Rev 37 (2001) 301-312
69. Veiga S., Garcia-Segura L.M., and Azcoitia I. Neuroprotection by the steroids pregnenolone and dehydroepiandrosterone is mediated by the enzyme aromatase. J Neurobiol 56 (2003) 398-406
70. Waldvogel H.J., Billinton A., White J.H., Emson P.C., and Faull R.L. Comparative cellular distribution of GABAA and GABAB receptors in the human basal ganglia: immunohistochemical colocalization of the alpha 1 subunit of the GABAA receptor, and the GABABR1 and GABABR2 receptor subunits. J Comp Neurol 470 (2004) 339-356
71. Watson R.R., Huls A., Araghinikuam M., and Chung S. Dehydroepiandrosterone and diseases of aging. Drugs Aging 9 (1996) 274-291
72. Weill-Engerer S., David J.P., Sazdovitch V., Liere P., Schumacher M., Delacourte A., et al. In vitro metabolism of dehydroepiandrosterone (DHEA) to 7alpha-hydroxy-DHEA and delta5-androstene-3beta,17beta-diol in specific regions of the aging brain from Alzheimer's and non-demented patients. Brain Res 969 (2003) 117-125
73. Wolf O.T., and Kirschbaum C. Actions of dehydroepiandrosterone and its sulfate in the central nervous system: effects on cognition and emotion in animals and humans. Brain Res Brain Res Rev 30 (1999) 264-288
74. Wolf O.T., Neumann O., Hellhammer D.H., Geiben A.C., Strasburger C.J., Dressendorfer R.A., et al. Effects of a two-week physiological dehydroepiandrosterone substitution on cognitive performance and well-being in healthy elderly women and men. J Clin Endocrinol Metab 82 (1997) 2363-2367
75. Zwain I.H., and Yen S.S. Dehydroepiandrosterone: biosynthesis and metabolism in the brain. Endocrinology 140 (1999) 880-887